The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 11, Pages 2560-2571
Publisher
Wiley
Online
2013-11-08
DOI
10.1002/ijc.28594
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinct HIC1-SIRT1-p53 Loop Deregulation in Lung Squamous Carcinoma and Adenocarcinoma Patients
- (2015) Ruo-Chia Tseng et al. NEOPLASIA
- HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma
- (2015) Chitra Subramanian et al. NEOPLASIA
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
- (2013) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Histone deacetylase 10 promotes autophagy-mediated cell survival
- (2013) I. Oehme et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
- (2012) Kwang Hwa Jung et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Histone deacetylases and cancer
- (2012) Bruna Barneda-Zahonero et al. Molecular Oncology
- Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines
- (2011) H Li et al. Advances in Medical Sciences
- The multiple roles of amphiregulin in human cancer
- (2011) Benoit Busser et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma
- (2011) Amandine Hurbin et al. JOURNAL OF PATHOLOGY
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
- (2011) Michele Cea et al. PLoS One
- The Deacetylase SIRT1 Promotes Membrane Localization and Activation of Akt and PDK1 During Tumorigenesis and Cardiac Hypertrophy
- (2011) N. R. Sundaresan et al. Science Signaling
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Mammalian Sirtuins: Biological Insights and Disease Relevance
- (2010) Marcia C. Haigis et al. Annual Review of Pathology-Mechanisms of Disease
- Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas
- (2010) Yoh Dobashi et al. HUMAN PATHOLOGY
- Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
- (2010) Christopher R. Garrett et al. INVESTIGATIONAL NEW DRUGS
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
- (2010) Kyle V. Butler et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype
- (2010) Jacques Cadranel et al. Journal of Thoracic Oncology
- Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization
- (2009) V Gama et al. CELL DEATH AND DIFFERENTIATION
- Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
- (2009) P. Laurent-Puig et al. CLINICAL CANCER RESEARCH
- Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation
- (2009) Benoît Busser et al. MOLECULAR THERAPY
- Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers
- (2009) Benoît Busser et al. MOLECULAR THERAPY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- SIRT3 Is a Stress-Responsive Deacetylase in Cardiomyocytes That Protects Cells from Stress-Mediated Cell Death by Deacetylation of Ku70
- (2008) N. R. Sundaresan et al. MOLECULAR AND CELLULAR BIOLOGY
- Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation
- (2008) Avigail D. Amsel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now